



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 8, 2024

Thomas Zindrick
Chief Executive Officer
Genelux Corporation
2625 Townsgate Road, Suite 230
Westlake Village, CA 91361

Re: Genelux Corporation
Registration Statement on Form S-3
Filed February 2, 2024
File No. 333-276847

Dear Thomas Zindrick:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Christine Kim